• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SWI/SNF复合物的BRG1溴结构域中的Tyr1497对选择性BRG1抑制剂的结合和功能至关重要。

Tyr1497 in the BRG1 Bromodomain of the SWI/SNF Complex is Critical for the Binding and Function of a Selective BRG1 Inhibitor.

作者信息

Wang Yinan, Yang Chuanhe, Miranda-Carboni Gustavo A, Kelso Hannah, Seetharaman Jayaraman, Hwang Dong-Jin, Miller Duane D, Pfeffer Lawrence M

机构信息

Department of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

Department of Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

出版信息

J Cell Mol Med. 2025 Mar;29(6):e70518. doi: 10.1111/jcmm.70518.

DOI:10.1111/jcmm.70518
PMID:40133216
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11936724/
Abstract

BRG1 and BRM are subunits of the SWI/SNF chromatin remodelling complex, which has DNA-stimulated ATPase activity and can destabilise histone-DNA interactions. Targeting SWI/SNF is beneficial for treating various tumours, including glioblastoma (GBM). Our research focussed on BRG1 due to its overexpression in GBM. We developed IV-255, a selective bromodomain (BRD) inhibitor that binds to BRG1 but not BRM. IV-255 sensitised GBM cells to temozolomide (TMZ), the standard GBM treatment. We identified the binding site of IV-255 within the BRG1 BRD and found that the Tyr1497 residue is crucial for IV-255's effect on TMZ-induced GBM cell death, while Asn1540 is not. Structural analyses confirmed that Tyr1497 is involved in the IV-255 binding pocket. Mechanistically, IV-255 increases γH2AX staining in GBM cell nuclei in response to TMZ, indicating an impaired DNA double-strand break response dependent on Tyr1497. IV-255 also sensitised GBM cells to TMZ-induced apoptosis, as shown by PARP and caspase-3 cleavage, which also requires Tyr1497. In conclusion, Tyr1497 within the BRD of BRG1 is critical for its interaction with IV-255 and for sensitising GBM cells to TMZ-induced DNA double-strand breaks and apoptotic cell death.

摘要

BRG1和BRM是SWI/SNF染色质重塑复合物的亚基,该复合物具有DNA刺激的ATP酶活性,能够破坏组蛋白与DNA的相互作用。靶向SWI/SNF对治疗包括胶质母细胞瘤(GBM)在内的各种肿瘤有益。由于BRG1在GBM中过表达,我们的研究聚焦于BRG1。我们开发了IV-255,一种选择性溴结构域(BRD)抑制剂,它能与BRG1结合但不与BRM结合。IV-255使GBM细胞对替莫唑胺(TMZ)(GBM的标准治疗药物)敏感。我们确定了IV-255在BRG1的BRD内的结合位点,发现Tyr1497残基对于IV-255对TMZ诱导的GBM细胞死亡的作用至关重要,而Asn1540并非如此。结构分析证实Tyr1497参与了IV-255结合口袋。从机制上讲,IV-255会使GBM细胞核中γH2AX染色增加以响应TMZ,这表明依赖于Tyr1497的DNA双链断裂反应受损。IV-255还使GBM细胞对TMZ诱导的凋亡敏感,如PARP和caspase-3的切割所示,这也需要Tyr1497。总之,BRG1的BRD内的Tyr1497对于其与IV-25

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/283cf369e2ca/JCMM-29-e70518-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/c72417955486/JCMM-29-e70518-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/ad84d88a4e01/JCMM-29-e70518-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/311395c49b0b/JCMM-29-e70518-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/0f620043906e/JCMM-29-e70518-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/550ca6d11ab0/JCMM-29-e70518-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/283cf369e2ca/JCMM-29-e70518-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/c72417955486/JCMM-29-e70518-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/ad84d88a4e01/JCMM-29-e70518-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/311395c49b0b/JCMM-29-e70518-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/0f620043906e/JCMM-29-e70518-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/550ca6d11ab0/JCMM-29-e70518-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b120/11936724/283cf369e2ca/JCMM-29-e70518-g006.jpg

相似文献

1
Tyr1497 in the BRG1 Bromodomain of the SWI/SNF Complex is Critical for the Binding and Function of a Selective BRG1 Inhibitor.SWI/SNF复合物的BRG1溴结构域中的Tyr1497对选择性BRG1抑制剂的结合和功能至关重要。
J Cell Mol Med. 2025 Mar;29(6):e70518. doi: 10.1111/jcmm.70518.
2
Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells.新型结构相关的 PFI-3(SRAPs)类似物靶向 SWI/SNF 复合物的 BRG1 催化亚基,增加胶质母细胞瘤细胞中替莫唑胺的活性。
Bioorg Med Chem. 2022 Jan 1;53:116533. doi: 10.1016/j.bmc.2021.116533. Epub 2021 Nov 27.
3
Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma.新一代 SWI/SNF 复合物的溴结构域抑制剂增强胶质母细胞瘤中的 DNA 损伤和细胞死亡。
J Cell Mol Med. 2023 Sep;27(18):2770-2781. doi: 10.1111/jcmm.17907. Epub 2023 Aug 18.
4
A novel nuclear RNA HSD52 scaffolding NONO/SFPQ complex modulates DNA damage repair to facilitate temozolomide resistance.一种新型核RNA HSD52支架NONO/SFPQ复合物调节DNA损伤修复以促进替莫唑胺耐药。
Neuro Oncol. 2025 May 15;27(4):963-978. doi: 10.1093/neuonc/noae272.
5
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
6
Glioblastoma stem cells deliver ABCB4 transcribed by ATF3 via exosomes conferring glioblastoma resistance to temozolomide.胶质母细胞瘤干细胞通过外泌体传递由 ATF3 转录的 ABCB4,使胶质母细胞瘤对替莫唑胺产生耐药性。
Cell Death Dis. 2024 May 6;15(5):318. doi: 10.1038/s41419-024-06695-6.
7
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.治疗胶质母细胞瘤进展或复发的选择:网络荟萃分析。
Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2.
8
Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent.美沙酮介导的脑胶质母细胞瘤细胞致敏作用具有药物和细胞系依赖性。
J Cancer Res Clin Oncol. 2021 Mar;147(3):779-792. doi: 10.1007/s00432-020-03485-3. Epub 2020 Dec 14.
9
MYC Regulates a DNA Repair Gene Expression Program in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.MYC调控高钙血症型卵巢小细胞癌中的一个DNA修复基因表达程序。
Cancers (Basel). 2025 Jul 7;17(13):2255. doi: 10.3390/cancers17132255.
10
Deciphering pericyte-induced temozolomide resistance in glioblastoma with a 3D microphysiological system mimicking the biomechanical properties of brain tissue.利用模拟脑组织生物力学特性的三维微生理系统解析胶质母细胞瘤中周细胞诱导的替莫唑胺耐药性。
Acta Biomater. 2025 Jun 15;200:202-217. doi: 10.1016/j.actbio.2025.05.038. Epub 2025 May 16.

本文引用的文献

1
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.BRG1/BRM 抑制剂靶向 AML 干细胞,并与 BET 或 menin 抑制剂联合发挥优异的临床前疗效。
Blood. 2024 May 16;143(20):2059-2072. doi: 10.1182/blood.2023022832.
2
Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma.新一代 SWI/SNF 复合物的溴结构域抑制剂增强胶质母细胞瘤中的 DNA 损伤和细胞死亡。
J Cell Mol Med. 2023 Sep;27(18):2770-2781. doi: 10.1111/jcmm.17907. Epub 2023 Aug 18.
3
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.
哺乳动物 SWI/SNF 染色质重塑复合物促进 EGFR 突变型肺癌对酪氨酸激酶抑制剂的耐药性。
Cancer Cell. 2023 Aug 14;41(8):1516-1534.e9. doi: 10.1016/j.ccell.2023.07.005. Epub 2023 Aug 3.
4
CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting.CB-Dock2:通过整合腔检测、对接和同源模板拟合来改进蛋白质配体盲目对接。
Nucleic Acids Res. 2022 Jul 5;50(W1):W159-W164. doi: 10.1093/nar/gkac394.
5
Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells.新型结构相关的 PFI-3(SRAPs)类似物靶向 SWI/SNF 复合物的 BRG1 催化亚基,增加胶质母细胞瘤细胞中替莫唑胺的活性。
Bioorg Med Chem. 2022 Jan 1;53:116533. doi: 10.1016/j.bmc.2021.116533. Epub 2021 Nov 27.
6
Targeting the Bromodomain of BRG-1/BRM Subunit of the SWI/SNF Complex Increases the Anticancer Activity of Temozolomide in Glioblastoma.靶向SWI/SNF复合物的BRG-1/BRM亚基的溴结构域可增强替莫唑胺对胶质母细胞瘤的抗癌活性。
Pharmaceuticals (Basel). 2021 Sep 6;14(9):904. doi: 10.3390/ph14090904.
7
Brahma-Related Gene-1 (BRG1) promotes the malignant phenotype of glioblastoma cells.Brahma 相关基因-1(BRG1)促进神经胶质瘤细胞的恶性表型。
J Cell Mol Med. 2021 Mar;25(6):2956-2966. doi: 10.1111/jcmm.16330. Epub 2021 Feb 2.
8
SMARCA2/4 PROTAC for Targeted Protein Degradation and Cancer Therapy.用于靶向蛋白降解和癌症治疗的SMARCA2/4 PROTAC
ACS Med Chem Lett. 2020 Jul 16;11(10):1797-1798. doi: 10.1021/acsmedchemlett.0c00347. eCollection 2020 Oct 8.
9
Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.发现具有口服活性的 Brama 同源物(BRM)/SMARCA2 ATP 酶活性抑制剂,用于治疗 Brama 相关基因 1(BRG1)/SMARCA4 突变型癌症。
J Med Chem. 2018 Nov 21;61(22):10155-10172. doi: 10.1021/acs.jmedchem.8b01318. Epub 2018 Oct 31.
10
Chromatin Remodeling Factor BRG1 Regulates Stemness and Chemosensitivity of Glioma Initiating Cells.染色质重塑因子 BRG1 调控神经胶质瘤起始细胞的干性和化疗敏感性。
Stem Cells. 2018 Dec;36(12):1804-1815. doi: 10.1002/stem.2909. Epub 2018 Nov 12.